Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) unit, Guangzhou Baiyunshan Tianxin Pharmaceutical, received approval from the Chinese drug regulator to make changes for its cefuroxime sodium for injection after it passed the regulator's consistency evaluation, according to a Shanghai Stock Exchange disclosure on Dec. 13.
The changes included amending the supplier of the drug's raw materials, the drug's quality standards, and the drug's packaging materials and containers, the pharmaceutical company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments